Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 670

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Study on the Effects and Safety of RO7204239 for Patients with Facioscapulohumeral Muscular Dystrophy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Humanised IgG1 monoclonal antibody against human latent myostatin

Colorectal cancer+6

Not recruiting

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280

Still's disease

Not recruiting

Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib

Hepatic cancer+1

Not recruiting

Study on Atezolizumab for Patients with Lung and Liver Cancer Using Digital Health Solutions

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Hidradenitis

Not recruiting

Study on Amlitelimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant

Sjogren's syndrome

Not recruiting

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide

Porphyria non-acute

Not recruiting

Study of Afamelanotide for Patients with Erythropoietic Protoporphyria (EPP)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Afamelanotide

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab

Neoplasm

Not recruiting

Study on the Safety of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.